Lung Cancer | Specialty

PORT Not Recommended as Standard of Care in Completely Resected Stage IIIAN2 NSCLC

September 20th 2020

Post-operative radiotherapy was linked with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non–small cell lung cancer and thus cannot be recommended as a standard of care for this population.

Dr. Solomon on the Results of the Phase 3 CROWN Study in ALK-Positive NSCLC

September 20th 2020

Benjamin Solomon, MBBS, PhD, FRACP, discusses interim findings from the phase 3 CROWN study in ALK-positive non–small cell lung cancer.

Frontline Lorlatinib Bests Crizotinib in Advanced ALK+ NSCLC

September 20th 2020

First-line treatment with the third-generation ALK TKI lorlatinib significantly improved progression-free survival, and also was associated with higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Neoadjuvant Durvalumab Induces Responses in Resectable NSCLC, But High Postsurgical Mortality Ends Study

September 19th 2020

Neoadjuvant durvalumab achieved a satisfactory complete surgical resection rate in patients with resectable non–small cell lung cancer, demonstrating preliminary promise for this treatment strategy.

Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC

September 19th 2020

One preoperative injection of atezolizumab was considered safe and induced major pathological responses in select patients with resectable non–small cell lung cancer.

EMA Recommends Approval of Nivolumab/Ipilimumab Plus Chemo in Frontline Metastatic NSCLC

September 18th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the frontline treatment of patients with metastatic non–small cell lung cancer.

Nivolumab/Ipilimumab Takes Step Toward EU Approval in Frontline Malignant Pleural Mesothelioma

September 17th 2020

The European Medicines Agency has validated a Type II Variation for nivolumab in combination with ipilimumab as a frontline treatment for previously untreated patients with unresectable malignant pleural mesothelioma.

Reducing the Impact of Chemotherapy-Induced Myelosuppression

September 16th 2020

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

September 16th 2020

CDK4/6 Inhibitors for SCLC: Trials of Interest

September 16th 2020

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

September 16th 2020

Analyses of CDK4/6 Inhibitors for Myelopreservation

September 16th 2020

CDK4/6 Inhibitors and Myelopreservation

September 16th 2020

Chemotherapy-Induced Myelosuppression & COVID-19

September 16th 2020

Management of Chemo-Induced Myelosuppression

September 16th 2020

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

September 16th 2020

Sequencing and Resistance Mechanism Challenges Arise in Biomarker-Driven NSCLC

September 15th 2020

Kartik Konduri, MD, discussed current treatment options that are available for patients with ALK, ROS1, and RET–positive NSCLC, as well as promising agents in the pipeline.

Osimertinib Eclipses Current Treatment Options in EGFR-Mutant NSCLC

September 14th 2020

Sawsan Rashdan, MD, discusses the current treatment paradigm of patients with resectable and metastatic EGFR-mutant NSCLC.

FDA Approves Oncomine Dx Target Test Companion Diagnostic for Pralsetinib in RET+ NSCLC

September 11th 2020

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with RET fusion–positive non¬–small lung cancer who are candidates to receive the recently approved targeted therapy pralsetinib.

Dr. Chiang on the Management of Immune-Related AEs in Lung Cancer

September 10th 2020

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer.